Excellent point you bring up as all questions need to be addressed.....
This has been addressed a few months back early in the year by a ST poster..He is good..here it is...
My points are 1) Tempol works for a myriad of indications. and 2) Yes, there are patent issues. But these can be worked around one way or another, even if there are NO patents, admittedly the extreme case. E.g., under the "unapproved drug initiative". Look up colchicine, where Takeda took a drug known to the ancient Egyptians and ran it thru just part of the regulatory mill. mdedge.com/rheumatology/art... Plenty of other drug companies have made
$BILLIONS
with less of a patent term coming out of regulatory approval. Stated-simply, Big pharma looked at the usual economics of spending $1-2 billion and 10 years for regulatory approval and decided to pass. But getting an EUA for Covid-19 is much cheaper and faster-- a few months and maybe $40-50 mil, tops.
One problem with Tempol is that it was too easy, obviating the usual necessity for some big expensive screening trial employing lots of people. This is difficult for some to contemplate or take seriously. A local derm doc with a pharma background just grabbed it off the shelf in the mid-1980's as a topical hairloss treatment agent and things went from there. patents.google.com/patent/U... Not even some Bay Area biotech worth a few 10's of millions, or a big university lab, much less Big Pharma.
Thanks Roll
AI
Market Data 
Markets 
